Novel computational pipelines in antiviral structure‑based drug design (Review)

Viral infections constitute a fundamental and continuous challenge for the global scientific and medical community, as highlighted by the ongoing COVID‑19 pandemic. In combination with prophylactic vaccines, the development of safe and effective antiviral drugs remains a pressing need for the effective management of rare and common pathogenic viruses. The design of potent antivirals can be informed by the study of the three‑dimensional structure of viral protein targets. Structure‑based design of antivirals <em>in silico</em> provides a solution to the arduous and costly process of conventional drug development pipelines. Furthermore, rapid advances in high‑throughput computing, along with the growth of available biomolecular and biochemical data, enable the development of novel computational pipelines in the hunt of antivirals. The incorporation of modern methods, such as deep‑learning and artificial intelligence, has the potential to revolutionize the structure‑based design and repurposing of antiviral compounds, with minimal side effects and high efficacy. The present review aims to provide an outline of both traditional computational drug design and emerging, high‑level computing strategies.